Collegium PharmaceuticalCOLL
About: Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Employees: 197
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
215% more call options, than puts
Call options by funds: $2.65M | Put options by funds: $842K
86% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 21
33% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 76
15% more capital invested
Capital invested by funds: $1.3B [Q2] → $1.49B (+$189M) [Q3]
8% more funds holding
Funds holding: 229 [Q2] → 247 (+18) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
3.65% less ownership
Funds ownership: 123.07% [Q2] → 119.42% (-3.65%) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Piper Sandler David Amsellem 47% 1-year accuracy 17 / 36 met price target | 25%upside $37 | Neutral Reiterated | 11 Oct 2024 |
Financial journalist opinion
